Business
Relmada Therapeutics Announces Poster Presentations at the American Psychiatric Association Annual Meeting 2021
NEW YORK, May 1, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous
About this update from Relmada Therapeutics, Inc.
[{"type":"text","content":"NEW YORK, May 1, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that clinical data related to REL-1017, the company's lead product candidate, will be presented in two posters at the American Psychiatric Association (APA) Annual Meeting 2021, which is being held virtually between May 1 and May 3, 2021.\n\n \n \n \n \n \n \n\n \nDetails of the poster presentations are below:\nDate/Time: May 1, 2021, from 1:00 – 1:30 PM ETPoster Number: 5181Title: Rapid and Sustained Antidepressant Effects of REL-1017 (esmethadone) as an Adjunctive Treatment for Major Depressive Disorder: A Phase 2 Trial \nDate/Time: May 1, 2021, from 1:00 – 1:30 PM ETPoster Number: 5198Title: Effect of Percentage of Life-Years from the Start of Major Depressive Disorder on the Therapeutic Response of REL-1017 \nThe on-demand posters are available for viewing online for the duration of the meeting by registered conference attendees. \nAbout REL-1017\nREL-1017, a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is entering late-stage studies as an adjunctive treatment for MDD in adults. Our clinical program for REL-1017 will evaluate its potential as the first rapid-acting, oral, once-daily antidepressant treatment. In a Phase 2 trial, REL-1017 demonstrated rapid onset and sustained antidepressant effects with statistically significant improvements as compared to placebo. The Phase 2 study also confirmed the favorable safety and tolerability profile of REL-1017 observed in previously completed Phase 1 studies. In April 2017, the FDA granted Fast Track designation for REL-1017 for the adjunctive treatment of major depressive disorder.\nAbout Relmada Therapeutics, Inc. \nRelmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmissio...